<DOC>
	<DOCNO>NCT02392507</DOCNO>
	<brief_summary>The purpose study determine nab-paclitaxel carboplatin chemotherapy plus necitumumab effective safe participant stage IV squamous non-small cell lung cancer .</brief_summary>
	<brief_title>A Study Nab-Paclitaxel Carboplatin Plus Necitumumab ( LY3012211 ) Participants With Stage IV Squamous NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have histologically cytologically confirm squamous NSCLC . Have stage IV disease time study entry ( American Joint Committee Cancer [ AJCC ] Staging Manual , 7th edition ) . Have measurable disease time study enrollment define Response Evaluation Criteria Solid Tumors , version 1.1 ( RECIST 1.1 ) . Have tumor tissue available biomarker analysis . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Have adequate organ function . Are currently enrol another clinical trial . Have receive prior anticancer therapy monoclonal antibody , signal transduction inhibitor , therapy target epidermal growth factor receptor ( EGFR ) , vascular endothelial growth factor ( VEGF ) , VEGF receptor . Have receive previous chemotherapy advance NSCLC . Participants receive adjuvant neoadjuvant chemotherapy eligible last administration prior regimens occur least 1 year prior study entry . Have undergone major surgery receive investigational therapy 4 week prior study entry . Have undergone systemic radiotherapy within 4 week prior study entry , focal radiotherapy within 2 week prior study entry . Have symptomatic central nervous system ( CNS ) malignancy metastasis ( screen require ) . Have history arterial venous embolism within 6 month prior study entry . Have clinical evidence concomitant infectious condition . Have know allergy / history hypersensitivity reaction treatment component , include ingredient use formulation necitumumab , contraindication one administer treatment . Are pregnant breastfeeding . Have know history drug abuse . Have concurrent active malignancy . Participants history malignancy eligible provide participant diseasefree â‰¥3 year , follow exception : Participants adequately treat basal squamous cell carcinoma skin , preinvasive carcinoma cervix , cancer judgment investigator Lilly clinical research physician/designee may affect interpretation result ( example , prostate , bladder ) eligible . Have discontinue investigational product non approve use drug device clinical trial within 30 day first day study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>